Drug Database
AL

albumin (Pedialb / AlbuRel / AlbuRel LS)

✓ Approved

Reliance Life Sciences Private Limited · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Reliance Life Sciences Private Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesPedialb, AlbuRel, AlbuRel LS
CompanyReliance Life Sciences Private Limited
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Reliance Life Sciences Private Limited

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedClinica chimica acta; international journal of clinical chemistry2026-05-24

Apolipoprotein B causes overestimation of serum albumin concentration measured by bromocresol green method in pediatric nephrotic syndrome patients.

Yang Qin Q, Peng Wan W, Wang Wenjuan W, Feng Qiulin Q et al.

Pediatric Nephrotic syndrome (PNS) is a prevalent major disorder in children. The precise detection of albumin is of crucial significance for the diagnosis, treatment decision-making, and prognosis improvement of PNS. The bromocresol green (BCG) method is a commonly used method for clinical albumin detection. Typically, patients with PNS exhibit disordered lipid metabolism, with altered levels of apolipoprotein B (ApoB), haptoglobin (Hp), and α2-macroglobulin (α2MG), apolipoprotein A1 (ApoA1). The objective of this study was to determine whether these proteins interfere with the detection of serum albumin using the BCG method in PNS, and to evaluate the extent of interference and its clinical implications. A total of 134 PNS patients were enrolled in the study. Serum albumin levels were measured simultaneously using both the BCG method (ALB-BCG) and the immunoturbidimetric assay (ALB-ITA). In addition, serum levels of Hp, α2MG, ApoB, and ApoA1 were measured and evaluated for their potential correlation with the discrepancy in albumin measurements between the two methods (ΔALB = ALB-BCG - ALB-ITA). Furthermore, to evaluate the interference of these proteins on albumin detection using the BCG or ITA method, an in vitro interference assay was performed by spiking purified proteins into standard albumin solutions at progressively increasing concentrations, thereby assessing their potential to interfere with albumin measurement. The children were stratified into three groups based on ALB-BCG levels, Group I, ALB-BCG ≥ 25 g/L (n = 43), Group II, 20 g/L ≤ ALB-BCG < 25 g/L (n = 35), Group III, ALB-BCG < 20 g/L (n = 56). Serum albumin concentrations measured by the BCG method were significantly higher than those obtained by the ITA method, with a difference (ΔALB) ranging from 0.2 to 6.9 g/L. ΔALB showed a significant negative correlation with serum albumin levels (P < 0.01). α2MG, ApoB, Hp and ApoA1 levels showed significant differences among the three groups (P < 0.05). ΔALB demonstrated moderate correlations with Hp, α2MG, and ApoB (P < 0.001), and a weak correlation with ApoA1 (P < 0.01). In vitro experiments demonstrated that ApoB caused a dose-dependent positive interference with the serum albumin detection using the BCG method (P < 0.001), but not with the ITA method. Although α2MG can bring about a slight decrease in ALB-BCG results (P = 0.024), it does not lead to a significant alteration in ΔALB. At physiological concentrations, Hp slightly raises ALB-BCG results, thus increasing ΔALB (P = 0.007), but the changes in ΔALB are only minimal. Elevated ApoB levels lead to a dose-dependent overestimation of albumin concentration when measured using BCG method. Thus, it is advisable to utilize the ITA method for the accurate determination of serum albumin levels in PNS patients. Meanwhile, when ITA is not readily available, the bromocresol purple (BCP) method can serve as a more practical alternative. This ensures a proper assessment of colloid osmotic pressure and nutritional status, thereby facilitating clinical diagnosis and therapeutic decision-making.

PMID 42176932
Read full article →
PubMedBMC emergency medicine2026-05-24

Diagnostic performance of the lactate dehydrogenase-to-albumin ratio for early acute kidney injury in crush syndrome: a retrospective cohort study.

Gür Ayşenur A, Yazıcı Ramiz R, Mutlu Hüseyin H, Öz Medine Akkan MA et al.

Crush syndrome is a life-threatening consequence of prolonged muscle compression, and acute kidney injury (AKI) is a major determinant of morbidity and mortality. Rapid AKI risk stratification at emergency department (ED) presentation remains challenging. We evaluated whether the lactate dehydrogenase-to-albumin ratio (LDAR) measured at ED admission could discriminate creatinine-defined AKI among patients with crush syndrome. We conducted a retrospective cohort study in the ED of a Level I trauma center from 1 January 2019 to 31 December 2025. Adults (≥ 18 years) meeting a predefined operational definition of crush syndrome, including traumatic compression injury, biochemical rhabdomyolysis, and compatible clinical or systemic features, were included. AKI was defined using serum creatinine-based Kidney Disease: Improving Global Outcomes criteria with a predefined approach for baseline creatinine determination. LDAR was calculated as admission lactate dehydrogenase divided by admission albumin. Discrimination was assessed using receiver operating characteristic (ROC) analysis with area under the curve (AUC) and 95% confidence intervals. Independent associations with AKI and RRT were examined using multivariable logistic regression. Among 512 patients, 180 (35.2%) were classified as having creatinine-defined AKI; 374 (73.0%) were male. Hemodialysis was required in 78/180 (43.3%) patients with AKI, and in-hospital mortality was higher in patients with AKI (15.0% vs. 0.6%). Creatine kinase (CK) showed the highest discrimination for AKI (AUC 0.977, 95% CI 0.964-0.989), followed by LDAR (AUC 0.966, 95% CI 0.953-0.980). A Youden-derived LDAR cut-off of ≥ 23.59 yielded 86.7% sensitivity and 96.7% specificity. In addition, an LDAR cut-off of ≥ 22.68 predicted RRT requirement in patients with CS with 97.4% sensitivity and 77.6% specificity. LDAR measured at ED presentation showed high discrimination for AKI and RRT in crush syndrome. Although not a stand-alone treatment trigger, it may support early renal risk stratification when interpreted together with CK, renal function, electrolyte status, and clinical severity. Not applicable.

PMID 42177412
Read full article →
PubMedJournal of pharmaceutical and biomedical analysis2026-05-24

Analytical quality by design-based development and validation of a robust impurity analysis method for albumin-bound paclitaxel nanoparticles.

Jeong Hye H, Gil Myung-Chul MC, Cho Young Ho YH, Lee Gye Won GW

Analytical Quality by Design (AQbD) was applied to develop a robust impurity (IMP) analysis method for albumin-bound paclitaxel nanoparticles (Nab-PTX). Preliminary studies revealed that the USP method could induce epimerization, increasing IMP VI (7-epi-paclitaxel) formation. Risk assessment (Ishikawa/FMEA) identified four critical method parameters: flow rate, acetonitrile ratio (ACN), column temperature, and formic acid (FA) content. A 27-run Box-Behnken design (BBD) and response surface modeling (R² = 0.8688-0.9950) revealed complex nonlinear relationships. Specifically, FA content suppressed the dissociation of carboxylic acid groups in early-eluting impurities, significantly improving peak symmetry. To overcome standard software limits, a multidimensional Method Operable Design Region (MODR) was constructed using Monte Carlo simulation (n = 50,000) with a custom Python-based script. Optimal conditions (1.1 mL/min, 40.5% ACN, 25 °C, 0.025% FA) were identified via desirability function (D=0.9589). Experimental verification showed high predictive accuracy (Bias -1.4% to +1.0%). The method was validated per ICH Q2(R1) guidelines, showing excellent linearity (R2≥0.9985), accuracy (87.8-106.2%), and precision (RSD≤0.59%). Notably, acidified sample preparation reduced method-induced IMP VI formation by > 75%, preventing false-positives. This study provides a systematic AQbD framework with computational integration for protein-bound nanomedicines, ensuring superior resolution and 33% faster analysis than compendial methods.

PMID 42176526
Read full article →
PubMedBMC nephrology2026-05-24

Associations between anthropometric, biochemical, and clinical factors and nutritional status in hemodialysis patients: an exploratory cross-sectional analysis.

Meriç Çağdaş Salih ÇS, Yılmaz Hacı Ömer HÖ, Yabancı Ayhan Nurcan N

This study aimed to investigate the associations and explore direct pathways between anthropometric measurements, biochemical parameters, and clinical characteristics in relation to nutritional status, assessed by Subjective Global Assessment (SGA), in patients undergoing maintenance hemodialysis (HD). This cross-sectional study included 93 adult HD patients recruited from a tertiary university hospital. Nutritional status was assessed using the SGA. Anthropometric measurements and biochemical parameters were evaluated. Group comparisons were performed using ANOVA and Chi-square tests. Univariate and multivariate logistic regression analyses were conducted to identify predictors of malnutrition, and exploratory path analysis was applied to examine patterns of association between selected clinical, anthropometric measurements, and nutritional status. Statistical significance was set at p < 0.05. According to the SGA, 68.8% of patients were classified as well-nourished; the mean age was 61.0 ± 14.1 years, and the mean Body Mass Index (BMI) was 25.0 ± 4.3 kg/m². Gender, multimorbidity (p < 0.05), older age, longer HD duration, and higher CRP levels (p < 0.001) were positively associated with malnutrition risk, while albumin and hemoglobin (p < 0.001) were negatively associated. In multivariate logistic regression analysis [OR (95% CI)], BMI (OR: 0.662, 95% CI: 0.445-0.985), serum albumin (OR: 0.03, 95% CI: 0.003-0.402), and hemoglobin (OR: 0.293, 95% CI: 0.112-0.761) were significant predictors of malnutrition risk (p < 0.05). In an exploratory path model accounting for 36% of the variance in SGA-defined nutritional status (R² = 0.36), BMI, age, and HD duration demonstrated significant standardized associations (β = -0.39, β = 0.30, and β = 0.31, respectively; all p < 0.001). Anthropometric measurements, routinely available biochemical parameters, and clinical characteristics provide complementary information for the assessment of nutritional status in patients undergoing maintenance HD. Age, HD duration, multimorbidity, and BMI emerged as clinically relevant factors associated with malnutrition risk across complementary analytical approaches. This research is a clinical assessment conducted on human participants but does not require intervention.

PMID 42177423
Read full article →
PubMedClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2026-05-24

Defining the unbound target exposure of teicoplanin part 2: Dose individualization through population pharmacokinetic modelling.

Mouton J W A JWA, Jager N G L NGL, Wallenburg E E, Schouten J A JA et al.

The pharmacokinetic index of teicoplanin is best described by the area of the unbound concentration under the concentration time curve (fAUC). In clinical practice the total trough concentration is used for the purpose of TDM. An fAUC24 of 75 mg·h/L has been proposed as a target. This study aimed to develop a population pharmacokinetic model based on unbound teicoplanin concentrations to evaluate and improve teicoplanin dosing. In this observational clinical trial 30 patients admitted to the ICU or hematology department were included. Dosing was at the discretion of the treating physicians. Samples were taken on day 2 (T=0, 1, 2 and 4) and day 5 (T= 0, 4, 8, 16 and 24) of therapy. Teicoplanin pharmacokinetics were characterized by Non-Linear Mixed Effects Modeling. The final model was used to simulate the probability of achieving an fAUC24 of 75-150 mg*h/L under current dosing regimens, and to evaluate the potential improvement through model-informed precision dosing. In total 188 samples were collected from 30 patients. Median full body weight was 80 kg [IQR 71-90], median eGFR (CKD-EPI) was 88 mL/min [IQR 46-117] and median serum albumin was 19.5 g/L [IQR 16-24]. Median unbound fraction was 21% [IQR 16-23]. A two-compartment pharmacokinetic model with eGFR as covariate for unbound clearance and albumin as covariate for Bmax best fitted the data. Simulations showed that probability of target attainment (PTA) in ICU patients is 58%. Failure to achieve the target was predominantly observed in patients with elevated eGFR. Simulations showed PTA can be augmented to 71% with improved dosing schedules, and to 91% when the model is applied to model-informed precision dosing. We developed a pharmacokinetic model capable of guiding teicoplanin dosing based on fAUC24. Current dosing schedules are suboptimal from a pharmacokinetic viewpoint. Model-informed precision dosing of unbound teicoplanin is advised to maximize target attainment.

PMID 42176739
Read full article →
PubMedBMC endocrine disorders2026-05-24

Relationship between vitamin D status, glycaemia and nephropathy in adults with type 2 diabetes mellitus.

Lawal-Bello Amina Titilayo AT, Soyoye David Olubukunmi DO, Ikem Rosemary Temidayo RT, Fasanu Ayodeji Nelson AN et al.

Diabetes mellitus (DM) remains a major cause of morbidity and mortality. Poor glycaemic control is a key determinant of diabetes-related complications, and vitamin D deficiency has emerged as a potential contributor to impaired glycaemic control. End-stage renal disease is one of the most severe complications of DM, imposing substantial individual and public health burdens. This study aimed to determine the prevalence and risk factors of vitamin D deficiency among patients with type 2 diabetes mellitus (T2DM) and to evaluate its association with glycaemic control and renal function. In this cross-sectional study, 100 patients with T2DM and 100 age- and sex-matched controls were recruited. Ethical approval was obtained, and informed consent was provided by all participants. Clinical data were collected, and physical examinations were performed. Blood samples were analysed for serum vitamin D, fasting blood glucose, 2-hour postprandial glucose, serum creatinine, lipid profile, albumin, calcium, and phosphate. Nephropathy was assessed using the urinary albumin-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). Data were analysed using SPSS version 23. The mean age of patients and controls was 53.0 ± 10.3 years and 52.9 ± 11.2 years, respectively (p = 0.933), with comparable sex distribution. Chronic kidney disease (stage ≥ 3) was present in 12.0% of T2DM patients and 4.0% of controls. Among T2DM patients, 14.0% had vitamin D deficiency (25(OH)D ≤ 20 ng/mL) and 31.0% had insufficiency (20-<30 ng/mL), compared with 5.0% and 20.0%, respectively, among controls. Vitamin D deficiency was more frequent in older participants and in males. A higher proportion of T2DM patients with vitamin D deficiency had nephropathy (93%) compared with those without deficiency. Independent predictors of vitamin D deficiency included increasing age (aOR = 1.086, 95% CI: 1.011-1.167; p = 0.024), male sex (aOR = 12.282, 95% CI: 2.661-56.688; p = 0.001), and higher glycated haemoglobin levels (aOR = 2.438, 95% CI: 1.511-3.934; p < 0.001). Vitamin D deficiency is common among individuals with T2DM and is associated with male sex, advancing age, poor glycaemic control, and nephropathy. Not applicable.

PMID 42177512
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin